

CARDIOGENICS HOLDINGS INC.

FORM NT 10-Q

(Notification that Quarterly Report will be submitted late)

Filed 03/17/16 for the Period Ending 01/31/16

Address 6865 SW 18TH STREET SUITE B13

BACA RATON, FL 33433

Telephone 905.673.8501

CIK 0001089029

Symbol CGNH

SIC Code 7389 - Business Services, Not Elsewhere Classified

Industry Scientific & Technical Instr.

Sector Technology

Fiscal Year 10/31



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 12B-25

SEC File Number: 000-28761 CUSIP Number: 14160X 203

NOTIFICATION OF LATE FILING

| Check One): [] Form 10-K [] Form 11-K [] Form 20-F [X] Form 10-Q [] Form N-SAR For Period Ended: Quarter ended January 31, 2016 Transition Report on Form 10-K [] Transition Report on Form 10-Q Transition Report on Form 10-K [] Transition Report on Form N-SAR Transition Report on Form 11-K For the Transition Period Ended: | | | 1,0111101111 | OI OI EITE TIEIN | | | | |
|---|-------------------------------|---|-------------------------------|-------------------------------|----------------------|----------------|--|--|
| Transition Report on Form 10-K Transition Report on Form 10-K Transition Report on Form 10-Q Transition Report on Form N-SAR Transition Report on Form N-SAR Transition Period Ended: Read attached instruction sheet before preparing form. Please print or type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: PART I REGISTRANT INFORMATION full name of Registrant CardioGenics Holdings Inc. Cormer name if applicable address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | (Check One): | [] Form 10-K | [] Form 11-K | [] Form 20-F | [X] Form 10-Q | [] Form N-SAR | | |
| Transition Report on Form 20-F Transition Report on Form N-SAR For the Transition Period Ended: Read attached instruction sheet before preparing form. Please print or type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: PART I REGISTRANT INFORMATION full name of Registrant CardioGenics Holdings Inc. | For Period F | Ended: Quarter ended Janu | ary 31, 2016 | | | | | |
| Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: PART I REGISTRANT INFORMATION full name of Registrant CardioGenics Holdings Inc. | Transition Rep Transition Rep | Transition Report on Form 20-F Transition Report on Form 11-K [] Transition Report on Form N-SAR | | | | | | |
| If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: PART I REGISTRANT INFORMATION Tull name of Registrant CardioGenics Holdings Inc. Cormer name if applicable Address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | Read attached in: | Read attached instruction sheet before preparing form. Please print or type. | | | | | | |
| PART I REGISTRANT INFORMATION full name of Registrant CardioGenics Holdings Inc. Cormer name if applicable Address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | Nothing in this fo | Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. | | | | | | |
| REGISTRANT INFORMATION full name of Registrant CardioGenics Holdings Inc. former name if applicable Address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | If the notification | n relates to a portion of the | filing checked above, identif | y the item(s) to which the no | tification relates: | | | |
| Address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | | | | | | | | |
| Address of principal executive office (Street and Number) 6295 Northam Drive, Unit 8 | Full name of Registra | ent | | CardioGenics Holdings | Inc. | | | |
| | Former name if applic | cable | | | | | | |
| Eity, state and zip code Mississauga, Ontario L4V 1WB | Address of principal of | executive office (Street and | d Number) | 6295 N | ortham Drive, Unit 8 | | | |
| | City, state and zip coo | de | | Mississauga, Ontario L4V | / 1WB | | | |
| | | | | | | | | |

PART II RULE 12b-25 (b) AND (c)

| | | ect report could not be filed without unrea Check box if appropriate.) | sonable effort or expense and the registrant seeks relie | of pursuant to Rule 12b-25(b), the following should | | |
|-----|------------------------|---|--|---|--|--|
| [X] | (a) | (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; | | | | |
| [X] | (b) | before the 15th calendar day following the | report, transition report on Form 10-K, 20-F, 11-K or F the prescribed due date; or the subject quarterly report or day following the prescribed due date; and | | | |
| [] | (c) | The accountant's statement or other exhi | bit required by Rule 12b-25(c) has been attached if app | licable. | | |
| | | | PART III NARRATIVE | | | |
| | | w in reasonable detail the reasons why Fo period. (Attach extra sheets if needed). | rms 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition | report portion thereof could not be filed within the | | |
| | | | the narrative and financial statements for the report we 31, 2016. The Registrant will file such report on or before the contraction of the contra | | | |
| | | | PART IV OTHER INFORMATION | | | |
| (| (1) Name a | and telephone number of person to contact | in regard to this notification | | | |
| , | | Yahia Gawad | (905) | 673-8501 | | |
| | | (Name) | (Area Code) | (Telephone Number) | | |
| | during th | | ction 13 or 15(d) of the Securities Exchange Act of 193 er period that the registrant was required to file such | | | |
| | | | | [X] Yes [] No | | |
| | | ticipated that any significant change in re e included in the subject report or portion | sults of operations from the corresponding period for t thereof? | he last fiscal year will be reflected by the earnings | | |
| | | | | [] Yes [X] No | | |
| | f so: attacts cannot b | | , both narratively and quantitatively, and, if appropriate | e, state the reasons why a reasonable estimate of the | | |

| | CardioGenics Holdings Inc. | | | | | |
|---------|---|--|--|--|--|--|
| | | (Name of Registrant as Specified in Charter) | | | | |
| has cau | has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized. | | | | | |
| Date | Date March 17, 2016 By: /s/ Yahia Gawad | | | | | |
| | | Name: Yahia Gawad | | | | |
| | | Title: Chief Executive Officer | | | | |
| | | | | | | |